Citadel Advisors
AURA icon

Citadel Advisors’s Aura Biosciences AURA Stock Holding History

Citadel Advisors’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,000
Closed -$35.2K – 12482
2025
Q1 		$35.2K Buy
6,000
+4,100
+216% +$31K ﹤0.01% 12657
2024
Q4 		$15.6K Sell
1,900
-29,700
-94% -$280K ﹤0.01% 13340
2024
Q3 		$282K Buy
31,600
+30,800
+3,850% +$264K ﹤0.01% 9466
2024
Q2 		$6.05K Buy
800
+400
+100% +$2.93K ﹤0.01% 13363
2024
Q1 		$3.14K Buy
400
+200
+100% +$1.66K ﹤0.01% 13942
2023
Q4 		$1.77K Buy
+200
New +$1.69K ﹤0.01% 13778
2023
Q3 		– Sell
-1,000
Closed -$12.3K – 14257
2023
Q2 		$12.3K Buy
+1,000
New +$10.7K ﹤0.01% 13083

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors's AURA Position: Q2 2026 in Review

Citadel Advisors increased its Aura Biosciences (AURA) stake by 315% in Q2 2026, buying an estimated $282K and bringing the position to 51,902 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #10634.

Citadel Advisors first reported a position in AURA in Q4 2021 and has held it in 18 quarters since. The position peaked at $48.3M in Q1 2022. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Citadel Advisors held 51,902 shares of Aura Biosciences worth $369K as of Q2 2026.
  • Citadel Advisors bought 39,399 Aura Biosciences shares in Q2 2026, an estimated $282K.
  • Aura Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10634 holding.
  • Citadel Advisors first reported a position in Aura Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Aura Biosciences position peaked at $48.3M in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.